Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Fixed-dose combination antihypertensive therapy is gaining interest following the JNC-VI report.
• Limited head-to-head comparative studies exist between fixed-dose combinations and first-line monotherapies for hypertension.

Purpose of the Study:

• To conduct a meta-analysis comparing various first-line monotherapies with the fixed-dose combination of amlodipine/benazepril.
• To evaluate the efficacy and safety of amlodipine/benazepril against first-line monotherapies.

Main Methods:

• Meta-analysis of 82 studies with 110 treatment groups.
• Comparison of nine monotherapies and one combination therapy (amlodipine/benazepril).
• Inclusion of placebo-controlled and active treatment-controlled studies.

Main Results:

• Amlodipine/benazepril demonstrated significant blood pressure (BP) reduction, comparable to top-performing monotherapies like verapamil and atenolol.
• The percentage of patients achieving controlled BP was highest with lisinopril and amlodipine/benazepril.
• Amlodipine/benazepril exhibited a lower-than-average incidence of overall adverse effects and the lowest rate of discontinuance due to side effects.

Conclusions:

• Amlodipine/benazepril provides effective BP lowering with a favorable safety profile.
• The fixed-dose combination therapy achieves its therapeutic goals with minimal significant side effects.
• This meta-analysis supports amlodipine/benazepril as a safe and effective option in hypertension management.